Drugs / Lopinavir/Ritonavir
Lopinavir/Ritonavir
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01088516 | Dec 2008 → Nov 2011 | HIV infectious disease | University of Zambia | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-27 | AbbVie | AbbVie Statement on Coronavirus and lopinavir/ritonavir abbvie.com ↗ |
| 2006-08-17 | Vertex Pharmaceuticals Incorporated | Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet vrtx.com ↗ |
| 2006-05-16 | Vertex Pharmaceuticals Incorporated | GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV vrtx.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lopinavir/Ritonavir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01088516 ↗ |
| Known as | Aluvia (Lopinavir/Ritonavir) | “Aluvia (Lopinavir/Ritonavir)” NCT01088516 ↗ |
| Known as | Kaletra | “tablet form of LOPINAVIR/RITONAVIR or LOP; established capsule form is known as Kaletra” NCT01088516 ↗ |
| Known as | LOP | “tablet form of LOPINAVIR/RITONAVIR or LOP; established capsule form is known as Kaletra” NCT01088516 ↗ |
| Route | Oral | “Lopinavir/Ritonavir (200/50 mg) two tablets PO BID” NCT01088516 ↗ |